Food Allergy Support

Discussion Boards => Allergy Research & News => Topic started by: LinksEtc on July 03, 2014, 05:30:58 PM

Title: Current barriers to adrenaline auto-injector use
Post by: LinksEtc on July 03, 2014, 05:30:58 PM
Tweeted by @Allergy

"Anaphylaxis treatment: current barriers to adrenaline auto-injector use"
http://onlinelibrary.wiley.com/doi/10.1111/all.12387/full?utm_content=bufferb6b2b&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer (http://onlinelibrary.wiley.com/doi/10.1111/all.12387/full?utm_content=bufferb6b2b&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer)

QuoteThe aim of this review is to highlight the barriers that exist to the use and availability of AAIs and that prevent proper management of anaphylaxis. In addition, we review the characteristics of all AAIs that are presently available in Europe and the USA and discuss the need for regulatory requirements to establish the performance characteristics of these devices.
Title: Re: Current barriers to adrenaline auto-injector use
Post by: LinksEtc on July 09, 2014, 02:24:53 PM
Tweeted by @AllergieVoeding

"Status of children with food allergy who were prescribed an adrenaline autoinjector (epipen)"
http://www.ncbi.nlm.nih.gov/pubmed/24865961?dopt=Abstract&utm_source=dlvr.it&utm_medium=twitter (http://www.ncbi.nlm.nih.gov/pubmed/24865961?dopt=Abstract&utm_source=dlvr.it&utm_medium=twitter)

QuoteCONCLUSION:
These results suggest that the autoinjector is often not used appropriately after prescription. Therefore, children and their caregivers require more effective guidance on proper adrenaline autoinjector use.